Cargando…
Enabling speed to clinic for monoclonal antibody programs using a pool of clones for IND-enabling toxicity studies
The importance of speed to clinic for medicines that may address unmet medical needs puts pressure on product development timelines. Historically, both toxicology and first-in-human clinical materials are generated using the same clonal-derived cells to ensure safety and minimize any development ris...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531531/ https://www.ncbi.nlm.nih.gov/pubmed/32449878 http://dx.doi.org/10.1080/19420862.2020.1763727 |